Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) reported Q4 2017 earnings this N/A, coming in at ($0.17) per share, beating Wall Street’s estimates of ($0.87) per Share. Revenue for the quarter came in at $3.77 million missing the streets estimates
Analyst Coverage For Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)
These are No ratings tracked in the last 12 months. .
The current consensus rating for Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) is N/A (Score: NaN) with a consensus target price of N/ARecent Insider Trading for Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)
- On 1/17/2017 Michael Sinclair, Insider, bought 3,500 with an average share price of $7.01 per share and the total transaction amounting to $24,535.00.
- On 1/17/2017 Roger Crystal, CEO, bought 3,475 with an average share price of $6.99 per share and the total transaction amounting to $24,290.25.
- On 1/13/2017 Kevin Pollack, Insider, bought 4,820 with an average share price of $6.98 per share and the total transaction amounting to $33,643.60.
Recent Trading for Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares of Opiant Pharmaceuticals, Inc. closed the previous trading session at with shares trading hands.